Why Is Everyone Talking About Novo Nordisk Stock?

Novo Nordisk's (NYSE: NVO) leading medications have been hot discussion topics for years. Many Americans might not recognize the Danish pharmaceutical company's name, but by now they've at least heard tell of its leading products: Wegovy, approved to treat obesity, and its sibling Ozempic, indicated for diabetes. Wegovy in particular is the subject of much talk because it offers a relatively easy way to lose weight.Despite the clear appeal of Novo Nordisk's famous drug, however, the stock hasn't been popular of late. Let's explore why, and determine if this makes the company's stock a buy at the moment.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool